About Eukaryotic translation initiation factor 3 subunit K
Eukaryotic translation initiation factor 3 subunit K (EIF3K) is a protein
from Homo sapiens identified by UniProt accession
Q9UBQ5, 218 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 3 subunit K |
|---|
| UniProt accession | Q9UBQ5 |
|---|
| Gene | EIF3K |
|---|
| Organism | Homo sapiens |
|---|
| Length | 218 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (110)
Diseases linked to this target (Open Targets).
- Hypomaturation amelogenesis imperfecta · score 0.07
- Romano-Ward syndrome · score 0.06
- Hypoplastic amelogenesis imperfecta · score 0.06
- Familial short QT syndrome · score 0.06
- Brugada syndrome · score 0.06
- familial atrial fibrillation · score 0.05
- Arrhythmogenic right ventricular dysplasia · score 0.05
- tooth agenesis · score 0.05
- Familial progressive cardiac conduction defect · score 0.05
- amelogenesis imperfecta · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UBQ5-F1 | alphafold | PREDICTED | 87.13 | — |
Amino-acid sequence (218 residues)
MAMFEQMRAN VGKLLKGIDR YNPENLATLE RYVETQAKEN AYDLEANLAV LKLYQFNPAF FQTTVTAQIL LKALTNLPHT DFTLCKCMID QAHQEERPIR QILYLGDLLE TCHFQAFWQA LDENMDLLEG ITGFEDSVRK FICHVVGITY QHIDRWLLAE MLGDLSDSQL KVWMSKYGWS ADESGQIFIC SQEESIKPKN IVEKIDFDSV SSIMASSQ
Explore Eukaryotic translation initiation factor 3 subunit K with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets